Exhaled Breath Analysis in Lymphangioleiomyomatosis by Real-Time Proton Mass Spectrometry
Authors:
- Malika MustafinaMMMalika Mustafina
- Artemiy SilantyevASArtemiy Silantyev
- Marina MakarovaMMMarina Makarova
- Aleksandr SuvorovASAleksandr Suvorov
- Alexander ChernyakACAlexander Chernyak
- Zhanna NaumenkoZNZhanna Naumenko
- Pavel PakhomovPPPavel Pakhomov
- Ekaterina PershinaEPEkaterina Pershina
- Olga SuvorovaOSOlga Suvorova
- Anna ShmidtASAnna Shmidt
- Anastasia GordeevaAGAnastasia Gordeeva
- Maria VergunMVMaria Vergun
Open Access
- 23 June 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6005
Abstract
Lymphangioleiomyomatosis (LAM) is a rare progressive disease that affects women of reproductive age and is characterized by cystic lung destruction, airflow obstruction, and lymphatic dysfunction. Current diagnostic methods are costly or lack sufficient specificity, highlighting the need for novel non-invasive approaches. Exhaled breath analysis using real-time proton mass spectrometry (PTR-MS) presents a promising strategy for identifying disease-specific volatile organic compounds (VOCs). This cross-sectional study analyzed exhaled breath samples from 51 LAM patients and 51 age- and sex-matched healthy controls. PTR-time-of-flight mass spectrometry (PTR-TOF-MS) was employed to identify VOC signatures associated with LAM. Data preprocessing, feature selection, and statistical analyses were performed using machine learning models, including gradient boosting classifiers (XGBoost), to identify predictive biomarkers of LAM and its complications. We identified several VOCs as potential biomarkers of LAM, including m/z = 90.06 (lactic acid) and m/z = 113.13. VOCs predictive of disease complications included m/z = 49.00 (methanethiol), m/z = 48.04 (O-methylhydroxylamine), and m/z = 129.07, which correlated with pneumothorax, obstructive ventilation disorders, and radiological findings of lung cysts and bronchial narrowing. The classifier incorporating these biomarkers demonstrated high diagnostic accuracy (AUC = 0.922). This study provides the first evidence that exhaled breath VOC profiling can serve as a non-invasive additional tool for diagnosing LAM and predicting its complications. These findings warrant further validation in larger cohorts to refine biomarker specificity and explore their clinical applications in disease monitoring and personalized treatment strategies.Keywords
Funding Information
- Russian Science Foundation (24-15-00549, 1023022600020-6)
- the government assignment (24-15-00549, 1023022600020-6)
This publication has 27 references indexed in Scilit:
- Exhaled breath analysis in adult patients with cystic fibrosis by real-time proton mass spectrometryClinica Chimica Acta, 2024
- MPoMA protects against lung epithelial cell injury via p65 degradationBiomedicine & Pharmacotherapy, 2024
- Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patientsJournal of Cystic Fibrosis, 2022
- Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and managementThe Lancet Respiratory Medicine, 2021
- Advances in proton transfer reaction mass spectrometry (PTR-MS): applications in exhaled breath analysis, food science, and atmospheric chemistryJournal of Breath Research, 2019
- Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Exhaled breath profiling using broadband quantum cascade laser-based spectroscopy in healthy children and children with asthma and cystic fibrosisJournal of Breath Research, 2016
- Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialThe Lancet Respiratory Medicine, 2013
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- Assessment of bronchial wall thickness and lumen diameter in human adults using multi‐detector computed tomography: comparison with theoretical modelsJournal of Anatomy, 2007